Rimegepant in Moderate Plaque-type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

August 20, 2024

Study Completion Date

November 18, 2024

Conditions
Psoriasis
Interventions
DRUG

Rimegepant

Active Agent

DRUG

Placebo

Placebo Comparator

Trial Locations (2)

10021

Weill Cornell Medicine, New York

10075

Sadick Dermatology, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER